… ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of … in Tübingen, Investigator in the ILLUMINATE trial. “ProQR’s RNA therapy for the p.Cys998X mutation showed the … Aniz Girach, Ophthalmologist and Chief Medical Officer of ProQR. “With the ongoing trials in LCA10 and Ushers syndrome …
… On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day LEIDEN, the Netherlands, Feb. … said Daniel A. de Boer, Chief Executive Officer of ProQR. “Together with our partners at the Leiden Bio Science … Sariette Witte Investor Relations T: +1 213 261 8891 ir@proqr.com …
… ProQR Announces Results for the Fourth Quarter and Full Year … said Daniel A. de Boer, Chief Executive Officer of ProQR. “QR-110, our second development program targeting … for QR-313 is expected to start in 2018. ProQR’s inaugural R&D day provides key updates on drug pipeline: On March 14 th …
… ProQR Highlights New Platform Data from Presentation on … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … mice,” said Gerard Platenburg, Chief Scientific Officer of ProQR. “To date, we have generated robust in vitro and in …
… ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen … & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … of sepofarsen. This marks an important milestone for ProQR, as well as for the LCA10 and broader inherited retinal …
… ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Key updates ProQR presents in vivo data in a relevant disease model, … The Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced that a …
